GlassScriptPhysician profile
Ann E Woolley
NPI 1205157625
$11,579.82
in general payments reported to CMS, 2019-2025
9 companies · $2,979 in 2025
The $2,979 reported for 2025 was more than what 88% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,901 · 2020: $1,000 · 2022: $130 · 2023: $79.75 · 2024: $1,490 · 2025: $2,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,954 · Food and Beverage: $545 · Travel and Lodging: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,954.00 |
| Food and Beverage | $544.73 |
| Travel and Lodging | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,775.00 | 2019 | |
| La Jolla Pharmaceutical Company | $2,467.91 | 2024-2025 | Zevtera, Xerava, Giapreza |
| Philips North America LLC | $1,205.00 | 2024 | (9520) Igt Devices Undivided |
| Paragonix Technologies, INC. | $1,000.00 | 2020 | |
| Intervascular | $655.00 | 2025 | Intergard |
| Takeda Pharmaceuticals U.S.A., INC. | $209.75 | 2022-2023 | Livtencity |
| United Therapeutics Corporation | $141.07 | 2024 | |
| Medtronic Vascular, INC. | $126.09 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Woolley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.